Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen
Kazia Therapeutics Limited - American Depositary Shares (KZIA)
US:NASDAQ Investor Relations:
kaziatherapeutics.com
Company Research
Source: PR Newswire
SYDNEY, Oct. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today reported a substantial reduction in tumor burden from a single-patient expanded access case in triple-negative breast cancer (TNBC) treated with a combination regimen that included the Company's investigational pan-PI3K/mTOR inhibitor, paxalisib. After three weeks of combination immunotherapy/chemotherapy plus paxalisib, imaging performed at the treating institution showed an 86% reduction in overall tumor burden.The patient is a 40+ year old female initially diagnosed with TNBC in April 2023. She received neoadjuvant chemotherapy and immunotherapy, followed by bilateral mastectomy six weeks post-treatment with no residual cancer detected, followed by radiation therapy. Approximately two years later, the patient was diagnosed with metastatic disease to bone and lungs. She was then treated under a single-patient expanded-access protocol with an immunothera
Show less
Read more
Impact Snapshot
Event Time:
KZIA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KZIA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KZIA alerts
High impacting Kazia Therapeutics Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
KZIA
News
- Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity SecuritiesPR Newswire
- Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy [Yahoo! Finance]Yahoo! Finance
- Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory StrategyPR Newswire
- Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsightPR Newswire
- Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsightPR Newswire
KZIA
Analyst Actions
- 10/2/25 - Maxim Group
KZIA
Sec Filings
- 12/5/25 - Form 6-K
- 12/2/25 - Form 6-K
- 11/18/25 - Form 424B3
- KZIA's page on the SEC website